189 related articles for article (PubMed ID: 31386648)
1. Jornay PM -- evening-dosed methylphenidate for ADHD.
Med Lett Drugs Ther; 2019 Aug; 61(1578):126-128. PubMed ID: 31386648
[No Abstract] [Full Text] [Related]
2. Azstarys (serdexmethylphenidate/dexmethylphenidate) for ADHD.
Med Lett Drugs Ther; 2021 Oct; 63(1634):157-159. PubMed ID: 34550957
[No Abstract] [Full Text] [Related]
3. Drugs for ADHD.
Med Lett Drugs Ther; 2020 Jan; 62(1590):9-15. PubMed ID: 31999670
[No Abstract] [Full Text] [Related]
4. Transdermal methylphenidate (Daytrana) for ADHD.
Med Lett Drugs Ther; 2006 Jun; 48(1237):49-51. PubMed ID: 16785850
[No Abstract] [Full Text] [Related]
5. Focalin XR for ADHD.
Med Lett Drugs Ther; 2009 Mar; 51(1308):22-4. PubMed ID: 19305368
[No Abstract] [Full Text] [Related]
6. Dexmethylphenidate extended release: a review of its use in the treatment of attention-deficit hyperactivity disorder.
Moen MD; Keam SJ
CNS Drugs; 2009 Dec; 23(12):1057-83. PubMed ID: 19958043
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy and safety of stimulants and non-stimulants in adults with attention deficit hyperactivity disorder (ADHD)].
Golubchik P; Sever J; Weizman A
Harefuah; 2011 Oct; 150(10):788-90, 814. PubMed ID: 22111124
[TBL] [Abstract][Full Text] [Related]
8. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
Chavez B; Sopko MA; Ehret MJ; Paulino RE; Goldberg KR; Angstadt K; Bogart GT
Ann Pharmacother; 2009 Jun; 43(6):1084-95. PubMed ID: 19470858
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder.
Pliszka SR; Wilens TE; Bostrom S; Arnold VK; Marraffino A; Cutler AJ; López FA; DeSousa NJ; Sallee FR; Incledon B; Newcorn JH
J Child Adolesc Psychopharmacol; 2017 Aug; 27(6):474-482. PubMed ID: 29172680
[TBL] [Abstract][Full Text] [Related]
10. Safe and effective methylphenidate therapy in a pediatric patient with glaucoma.
Lewis H; Lewis J
Atten Defic Hyperact Disord; 2012 Mar; 4(1):37-9. PubMed ID: 22311620
[TBL] [Abstract][Full Text] [Related]
11. Methylphenidate and dexmethylphenidate formulations for children with attention-deficit/hyperactivity disorder.
Sugrue D; Bogner R; Ehret MJ
Am J Health Syst Pharm; 2014 Jul; 71(14):1163-70. PubMed ID: 24973373
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of Ritalin LA, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder.
Biederman J; Quinn D; Weiss M; Markabi S; Weidenman M; Edson K; Karlsson G; Pohlmann H; Wigal S
Paediatr Drugs; 2003; 5(12):833-41. PubMed ID: 14658924
[TBL] [Abstract][Full Text] [Related]
13. A double-blind, randomized, placebo/active controlled crossover evaluation of the efficacy and safety of Ritalin ® LA in children with attention-deficit/hyperactivity disorder in a laboratory classroom setting.
Schulz E; Fleischhaker C; Hennighausen K; Heiser P; Oehler KU; Linder M; Haessler F; Huss M; Warnke A; Schmidt M; Schulte-Markworth M; Sieder C; Klatt J; Tracik F
J Child Adolesc Psychopharmacol; 2010 Oct; 20(5):377-85. PubMed ID: 20973708
[TBL] [Abstract][Full Text] [Related]
14. Cotempla XR-ODT--another long-acting methylphenidate for ADHD.
Med Lett Drugs Ther; 2017 Nov; 59(1533):183-185. PubMed ID: 29125594
[No Abstract] [Full Text] [Related]
15. Quillivant XR--an extended release oral suspension of methylphenidate.
Med Lett Drugs Ther; 2013 Feb; 55(1409):10-1. PubMed ID: 23381227
[No Abstract] [Full Text] [Related]
16. Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder.
Wolraich ML; Greenhill LL; Pelham W; Swanson J; Wilens T; Palumbo D; Atkins M; McBurnett K; Bukstein O; August G
Pediatrics; 2001 Oct; 108(4):883-92. PubMed ID: 11581440
[TBL] [Abstract][Full Text] [Related]
17. Cmap ADHD and comorbid aggression algorithm.
Sharp BW
J Am Acad Child Adolesc Psychiatry; 2007 Jan; 46(1):1. PubMed ID: 17195721
[No Abstract] [Full Text] [Related]
18. OROS methylphenidate-induced skin eruptions.
Coskun M; Tutkunkardas MD; Zoroglu S
J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):593-4. PubMed ID: 19877987
[No Abstract] [Full Text] [Related]
19. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
[TBL] [Abstract][Full Text] [Related]
20. [Attention deficit disorder with hyperactivity (ADHD). Continuing symptom control with medium term methylphenidate treatment].
Oberpichler-Schwenk H
Med Monatsschr Pharm; 2006 Nov; 29(11):415-6. PubMed ID: 17131689
[No Abstract] [Full Text] [Related]
[Next] [New Search]
